We were delighted to speak to Christopher Ritchlin (University of Rochester, Henrietta, NY, USA) about the one year results from the DISCOVER-1 Phase 3 trial of guselkumab in active psoriatic arthritis (Clinical Trial Identification: NCT03162796). The abstract ‘Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced.’ (ABSTRACT NUMBER: 1344) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- What are the major unmet needs in the treatment of patients with active psoriatic arthritis? (0:16)
- What is guselkumab and what is its mechanism of action? (1:39)
- Could you tell us a little about the aims and design of the Phase 3 clinical study you are presenting? (2:56)
- What were the efficacy and safety findings of this study? (4:43)
- What are the implications of these findings for clinical practice? (5:31)
Disclosures: Consultant: Janssen, Abbvie, Amgen, UCB, Sanofi, Novartis, Lilly, Gilead
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Maarten Boers, EULAR 2021: Findings from the ULTIMATE Clinical Trial
It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial. The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with […]
Xenofon Baraliakos, EULAR 2021: Findings from the MAXIMISE Study
It was a pleasure to meet with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Herne, Germany) to talk around his presentation on ‘Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial.‘ (POS0930), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. Questions […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!